FDA Grants Fast Track Designation to PBGENE-DMD for Duchenne Muscular Dystrophy
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, its novel gene editing therapy designed to treat Duchenne muscular dystrophy (DMD).
/ 1 item
#DTIL↓